



Your Imaging & Radiation Oncology CRO

SCIENTIFIC EXPERTISE

MEDICAL EXPERTISE

PROPRIETARY TECHNOLOGY

IMAGING & RT

CLINICAL TRIALS


ONCOLOGY SPECIALIST

ABOUT OUR EXPERTISE

AQUILAB is an **Imaging and Radiation Oncology** CRO, specializing in supporting oncology clinical trials through our in-depth expertise in radiotherapy and imaging data management.

With over 25 years of experience in these fields, we have developed advanced technological solutions to optimize the quality, efficiency, and compliance of oncology clinical trials. Our **proprietary platform**, OncoPlace, enables seamless management of imaging and radiotherapy data, ensuring their integrity and facilitating the validation of study results.

imaging CRO




+15
years of experience

+4000
users


+100
clinical trials

+800
sites worldwide

Study Phase



Therapeutic Area



ABOUT OUR TECHNOLOGIES



ONCOPLACE

OUR SOLUTION FOR CROs MANAGING IMAGING & RT DATA

Onco Place is the AQUILAB by Coexya platform to efficiently Share and Analyze Imaging and Radiotherapy data in your clinical trials.

Onco Place is all-in-one solution, with unmatched customization possibilities, to fit any of your requirements. It provides an efficient way to improve coordination and ensure trial quality while saving time and reducing overall costs.



COLLECTING

STRUCTURING

REVIEWING


ANALYZING

PATIENTPLACE

EPRO PLATFORM TO COLLECT YOUR PATIENT DATA

Patient Place is the AQUILAB by Coexya platform that allows you to customize your patient questionnaires and set up automatic reminders to keep patients engaged and informed throughout the clinical trial process.

Eliminate paper forms to collect data from participants, whether they are on-site or halfway around the world, using various devices (tablets, phones, computers...).



CONFIGURABLE

CONNECTED

AUTOMATED

SECURED

HOW TO BECOME A PARTNER ?

CONTACT US

Sales Rep
Oncology



Pierre DHAUSSY

pierre.dhaussy@aquilab.com

Oncology Product
Manager



Sandrine DUCORNET

sandrine.ducornet@aquilab.com

BU Director
Oncology



David GIBON

david.gibon@aquilab.com

THEY USED OUR EXPERTISE

Vera, P. et al. [2024] '[Adaptive radiotherapy \(up to 74 Gy\) or standard radiotherapy \(66 Gy\) for patients with stage III non-small- cell lung cancer, according to \[18F \] FDG-PET tumour residual uptake at 42 Gy \(RTEP7 – IFCT-1402\): a multicentre, randomised , controlled phase 2 trial](#)', The Lancet Oncology, 25(9), pp. 1176-1187.

Journy, N. et al. [2024] '[Assessing late outcomes of advances in radiotherapy for paediatric cancers: Study protocol of the “HARMONIC-RT” European registry \(NCT 04746729\)](#)', Radiotherapy and Oncology, 190(September 2023), pp. 1016–1019.

Modesto, A. et al. [2023] '[Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carcinoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol](#)', BMC Cancer, 23(1), pp. 1–9.

Sarrade, T. et al. [2023] '[CANTO-RT: One of the Largest Prospective Multicenter Cohort of Early Breast Cancer Patients Treated with Radiotherapy including Full DICOM RT Data](#)', Cancers, 15(3), p. 751.

Le Quellenec, G. et al. [2023] '[Post-operative flank irradiation using conformal versus highly conformal radiotherapy techniques for paediatric renal tumours: Results from the French registry PediaRT](#)', Pediatric Blood and Cancer, 70(11), pp. 1–15.

Desrousseaux, J. et al. [2023] '[Respective Roles of Surgery, Chemotherapy, and Radiation Therapy for Recurrent Pediatric and Adolescent Ependymoma: A National Multicentric Study](#)', International Journal of Radiation Oncology Biology Physics, 117(2), pp. 404–415.